Low-molecular-weight heparin (LMWH) rather than warfarin is routinely recommended for patients with venous thromboembolism (VTE) and active cancer.  Much of that is based on this article.

Think about these as you review the article:

• Clinical Question: In patients with cancer and VTE, is LMWH as effective as (or better than) warfarin for the secondary prevention of VTE?
• How does the hazard ratio compare between LMWH and warfarin for the primary outcome?
• How effective (i.e. compliant) were the patients in each study arm?